arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked

The Future of CAR-T Cell Therapy

Rome |
Speakers include:
Valentino Confalone

Valentino Confalone

Gilead Italia

Franco Locatelli

Franco Locatelli

IRCCS Bambino Gesù Children’s Hospital

Francesco De Lorenzo

Francesco De Lorenzo

University Federico 11 of Naples: President of the Italian Federation of Cancer Patients Organisations (FAVO)

Overview

With recent approvals for CAR-T cell therapies for use in patients in both the US and Europe, attention now turns to the next big challenge - ensuring that these innovate therapies make their way to patients. Italy has been a pioneer in CAR-T cell therapy development with the first commercially available therapy developed in this market, yet the challenges the country now faces in terms of a lack of availability and investment in appropriate clinical infrastructure and services for the delivery these therapies to patients is illustrative of a broader international trend.

Hosted by the Financial Times, in partnership with Gilead Sciences, this event will bring together stakeholders from government, clinicians, healthcare providers and industry to discuss the challenges and solutions  in ensuring CAR-T becomes a reality for patients.

fallback
fallback Add to my Calendar 02/06/2020 09:15:0002/06/2020 12:00:00trueThe Future of CAR-T Cell TherapyWith recent approvals for CAR-T cell therapies for use in patients in both the US and Europe, attention now turns to the next big challenge - ensuring that these innovate therapies make their way to patients. Italy has been a pioneer in CAR-T cell therapy development with the first commercially available therapy developed in this market, yet the challenges the country now faces in terms of a lack of availability and investment in appropriate clinical infrastructure and services for the delivery these therapies to patients is illustrative of a broader international trend.Hosted by the Financial Times, in partnership with Gilead Sciences, this event will bring together stakeholders from government, clinicians, healthcare providers and industry to discuss the challenges and solutions  in ensuring CAR-T becomes a reality for patients.The-Future-of-CAR-T-Cell-Therapyec3c46bf949fd5b38a94fb65f06f78eeMM/DD/YYYY

Agenda - 6th Feb

  • 9:15am
    Arrivals
  • 9:30am
    Welcoming remarks

    Donato Mancini, Reporter, Financial Times
    Valentino Confalone, Vice President, General Manager, Gilead Sciences Italia

  • 9:45am
    The future of CAR-T: An Italian market perspective
    • The landscape for CAR-T in Italy: what has been achieved, where do we go from here?
    • How can healthcare systems be better aligned with the introduction of CAR-T and other advanced therapies?
    • How do you build institutional readiness for CAR-T? Will systems be able to meet the patient demand  for CAR-T and other advanced therapies coming online?
    • What is the delivery infrastructure that will be needed, and the new delivery models that will emerge?
    • What are the lessons, insights and best practices from the experiences of other countries ?

    Professor Franco Locatelli, Head of Department of Paediatric Haematology and Oncology, IRCCS  Bambino Gesù Children's Hospital

  • 10:05am
    A patient group perspective
    • What are the benefits and challenges of CAR-T from the patient perspective?
    • How could patient access and experience be improved? Addressing the issues of cost, logistics, information, referrals, trial recruitment and accessibility
    • Beyond therapy: the importance of counselling , support and ancillary services

    Francesco De Lorenzo, President, Italian Federation of Cancer Patients Organisations (FAVO)

  • 10:25am
    A new treatment paradigm: How will CAR-T transform clinical care?
    • What are the specific clinical and non-clinical needs of patients undergoing CAR-T ?
    • What are the views of front-line clinicians on how current healthcare delivery systems need to be transformed to make way for CAR-T and other advanced and highly personalised therapies?
    • What are the skills challenges and how can they be addressed? 

    Alessandro Rambaldi, Professor of Haematology, University of Milan

  • 10:45am
    Beyond R&D: what can the government do to ensure cell therapies and personalised medicine reach their full potential for patients?
    • How can the public and private sector work together to make CAR-T available for patients as demand for these innovative therapies continues to grow?
    • Overcoming barriers to patient access to CAR-T (regional budgets constraints and accounting practices, medical education and working practices, infrastructure constraints, regional variations in availability of appropriate treatment centres): What is the policy response?

    Pierpaolo Sileri, Vice Minister of Health, Italy

  • 11:15am
    Panel: Making CAR-T a reality for patients

    CAR-T is a huge step for cancer treatment and personalised medicine requiring significant changes to the way healthcare delivery systems and services are configured, and new infrastructure to expand the delivery and uptake of therapies by patients. Stakeholders must engage with each other to ensure CAR-T reaches its full potential.

    Francesco De Lorenzo, President, Italian Federation of Cancer Patients Organisations (FAVO)
    Professor Franco Locatelli, Head of Department of Paediatric Haematology and Oncology, IRCCS Bambino Gesù Children's Hospital
    Alessandro Rambaldi, Professor of Haematology, University of Milan  
    Moderator: Marco Vulpiani,  Head of Valuation, Modelling  and Economics; Central Mediterranean Life Sciences Leader, Deloitte

  • 11:55am
    Closing remarks
  • 12:00pm
    Close of event

Speakers (4)

Valentino Confalone

Valentino Confalone

Vice President and General Manager
Gilead Italia

Valentino Confalone is Vice President and General Manager of Gilead Sciences Italia, a position he has held since 2017.

Prior to joining Gilead, Mr Confalone was with Bristol-Myers Squibb, where he held roles of increasing responsibility at a national and international level, including Director of the Virology in France, Market Access Lead in Oncology for Europe, and General Manager for Portugal. He began his career in the pharmaceutical sector in the Spanish branch of Schering Plough.

Mr Confalone graduated with a degree in Economics from the Federico II University of Naples, He later obtained a Master's degree in International Relations and an MBA from the IESE Business School in Barcelona.

Franco Locatelli

Franco Locatelli

Head of the Department of Paediatric Haematology and Oncology
IRCCS Bambino Gesù Children’s Hospital

Franco Locatelli is the Head of the Department of Paediatric Haematology and Oncology, IRCCS Bambino Gesù Children’s Hospital and Full Professor of Paediatrics at the Sapienza, University of Rome, Italy. He leads the largest programme of childhood allogeneic haematopoietic stem cell transplantation (HSCT) in Italy and was recently appointed President of the Italian Higher Council of Health, the technical scientific advisory body to the Ministry of Health. Professor Locatelli is an expert in haematological and oncological malignancies of childhood. He was  President of the Italian Association for Paediatric Haematology-Oncology from 2004–2006, and served as Chairman of the EWOG-MDS consortium from 2005 to 2011. Currently, he coordinates the national protocols for children with newly diagnosed acute myeloid leukaemia and relapsed acute lymphoblastic leukaemia (ALL). He has implemented in Italy the first-in-human academic studies on children with CD19+ lymphoid malignancies using 2nd generation retroviral chimeric antigen receptor (CAR) T cells and on children with GD2+ neuroblastoma. Professor Locatelli is also involved in the development and validation of gene therapy approaches in patients with thalassaemia and sickle cell disease and has extensive experience in running Phase I/II clinical trials. He is the author or co-author of 1.025 peer-reviewed articles published in international journals.

Francesco De Lorenzo

Francesco De Lorenzo

Professor Emeritus in Biochemistry
University Federico 11 of Naples: President of the Italian Federation of Cancer Patients Organisations (FAVO)

Professor Francesco De Lorenzo  is  a cancer colon survivor with a 22 years of experience in patient advocacy, capacity building, research, networking building, policy, partnership and project design and management. He is currently Professor Emeritus of Biochemistry at the University Federico II of Naples. He also services as Chair of the Scientific Committee and Past President of the European Cancer Patient Coalition (ecpc.org); President of the Italian Federation of Cancer Patients Organisations (favo.it) and President of the Italian Association for Cancer Patients (aimac.it). In addition, he serves as a Board member of the following organisations: European Academy of Cancer Science ; Cancer Core Europe; CDDF-The Cancer Drug Development Forum ;Innovative Partnership for Action Against Cancer; Elite Oncology Roundtable, under the auspices of the Society for Translational Oncology and the Alliance Against Cancer, the largest Italian organisation for cancer research. He has been actively involved in the European Commission Expert Group on Cancer Control; European Partnership Action Against Cancer Joint Action; Joint Action on Cancer Control ; Joint Action on  Rare Cancer  and the Italian National Cancer Plan. He is also the author of numerous scientific papers to include his latest publications:  F. De Lorenzo, K. Apostolidis: ECPC and its central role in connecting stakeholders to advance patient centric solutions in the mission on cancer, Journal of Molecular Oncology, 2019; A. M. Eggermont, F. De Lorenzo & al: Cancer Core Europe: A translational research infrastructure for a European mission on cancer, Journal of Molecular Oncology, 2019:P. Lagergren, F. De Lorenzo & al: Cancer survivorship: an integral part of Europe’s research agenda, Molecular Oncology, 2019; A. Berns, F. de Lorenzo , & al: Towards a Cancer Mission in Horizon Europe, Molecular Oncology, 2019.

Alessandro Rambaldi

Alessandro Rambaldi

Professor of Haematology
University of Milan

Alessandro Rambaldi, MD, is Full Professor of Hematology of the Department of Oncology and Hematology at the University of Milan, Italy. Following his medical degree, he was Associate in Pathology at the Dana Farber Cancer Institute, Boston, USA. Since 2006 he is the Director of the Hematology and Bone Marrow Transplant Unit at the Ospedale Papa Giovanni XXIII, Bergamo, Italy. He is member of the American Society of Hematology (ASH), European Hematology Association (EHA), European Blood and Marrow Transplant group (BMT). From 2010 he served JACIE as Vice Chair and Chair from 2010 to 2015. From 2011 to 2014 he was President of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Professor Rambaldi’s scientific interest ranges from translational research to academic clinical trials in which he pioneered the integration of molecular evaluation of minimal residual disease in the treatment strategy of adult patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphomas.  He also led several trials in the field of allogeneic transplantation, mainly evaluating the role of reduced toxicity conditioning regimen in AML and other malignancies. A current special research interest is the development of innovative cellular therapies for the treatment of leukemia relapse after allogeneic stem cell transplantation.

Professor Rambaldi has published more than 500 publications in peer-reviewed journals such as Lancet Oncology, JCO, Blood and Leukemia for which he routinely serves as referee. He is member of the editorial board of the Journal of Clinical Oncology.

fallback

Chair and Moderator (2)

Marco Vulpiani

Marco Vulpiani

Head of the Valuation, Modelling and Economics:Central Mediterranean Life Science Sector Leader.
Deloitte

Marco Vulpiani is a Senior Equity Partner of Deloitte, and is the firm’s Head of the Valuation, Modelling and Economics service line in Italy.  He also serves as Deloitte’s Central Mediterranean Life Science Sector Leader. He gained a significant experience in the life Science and healthcare industry, with primary clients such as Pfizer, Sanofi, MSD, Sigma Tau, Merck Serono, Boehringer Ingelheim, GSK, among others. He also has 25 years of professional experience focused principally on business valuation.  

In addition to these roles, Dr Vulpiani serves on the Deloitte Global Valuation Executive Committee and is a member of the Management Board of the Italian valuation standard setter  “Organismo Italiano di Valutazione” (OIV).  He is also Adjunct Professor of “Business Valuation” at Luiss Guido Carli University of Rome and Adjunct Professor in the MBA, Master in Corporate Finance and Executive Master in Finance at Luiss Business School.  He is author of several articles and publications (among which the book Special Cases of Business Valuation, McGraw-Hill)

Dr Vulpani he is a Registered Engineer, a Chartered Accountant and a Registered Auditor. He holds a PhD in Business Administration from the University of Rome “Tor Vergata”, a Master of Science in Business Administration from the University of Rome “Tor Vergata” and a Master’s Degree in Aeronautical Engineering from the University of Rome “La Sapienza”.

Donato Paolo Mancini

Donato Paolo Mancini

Reporter
Financial Times

Donato Paolo Mancini covers companies at the Financial Times, with a particular interest in R&D, pharma and regulation. His reporting is aimed at exploring how the social contract between the public, research and regulators can best address unmet need, and how companies can aim to be profitable while ensuring access is as wide as possible. He joined the FT in 2019 having previously worked at the Wall Street Journal and Dow Jones, where he also wrote about pharma among other topics. His first reporting assignment was in Istanbul, covering the Gezi Park protests of 2013, and he’s covered major corporate and news events since.

Venue

Ministero della Salute
Alla c.a. sig. Claudio Ponti
Viale Giorgio Ribotta n. 5
Rome 00144

Italy

Tel: 0039 06 59941

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Organised and Funded by (1)

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Contact Us

Joe Hames
Sponsorship & Exhibitor Opportunities
Financial Times
Abigail Lewis
Project Manager - Strategic Solutions
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times